ADVISORY/Eli Lilly and Co.: Media Alert: Update on Strattera: A New Type of Medication for ADHD.Business Editors and Health/Medical Writers ADVISORY...for October 25 (Friday) INDIANAPOLIS--(BUSINESS WIRE)--Oct. 24, 2002 Leading researchers will provide an important update on Strattera(TM) (atomoxetine hydrochloride atomoxetine hydrochloride Strattera Pharmacologic class: Selective norepinephrine reuptake inhibitor Therapeutic class: Central nervous system agent Pregnancy risk category C ), an investigational treatment for Attention-Deficit/Hyperactivity Disorder, during a national meeting of child and adolescent ad·o·les·centadj. Of, relating to, or undergoing adolescence. n. A young person who has undergone puberty but who has not reached full maturity; a teenager. psychiatrists This list includes notable psychiatrists. Individuals listed below are all physicians, and are board certified by the American Board of Psychiatry and Neurology, or are members of the American Psychiatric Association, or the Royal College of Psychiatrists in the United Kingdom, or in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden . This update will include: -- Data from studies of Strattera's efficacy in children, adolescents and adults, including new data on dosing, onset of action and effects on evening activities -- An overview of Strattera's clinical development -- Long-term safety data -- An assessment of Strattera's potential place, after approval, among ADHD treatment options available to physicians. In addition, Strattera investigators will be available for interviews. In August, the U.S. Food and Drug Administration issued an approvable letter for Strattera, indicating the agency is prepared to grant final approval once certain conditions are met. If approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , Strattera would be the first new type of medication for the treatment of ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or in decades.
WHAT: Symposium on Strattera
WHEN: Friday, October 25, 1 pm PDT
WHERE: A national meeting of child and adolescent psychiatrists in
San Francisco
WHY: Get up-to-date information on Strattera, a new type of
medication for ADHD. Strattera received an approvable letter
from the FDA in August and is awaiting final approval.
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion